Evidence map›Paper›PMID 42278639›Full record

ReviewInternational journal of molecular sciences2026

Chronic Lymphocytic Leukemia: Molecular Pathologies and Therapeutic Strategies.

Kelly Meza, Carla Barrientos Risso, Ankit Shah, Carla Romagnoli, Jose Sandoval, Yelida Brauchle, Alexandra Lyubimova, Leily Santos, Evelyn Goya Balaguer, Jacqueline Barrientos

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kelly MezaDepartment of Internal Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
Carla Barrientos RissoBaystate Medical Center, University of Massachusetts Chan Medical School, Springfield, MA 01107, USA.
Ankit ShahDepartment of Medicine, Division of Hematology/Oncology, Rutgers New Jersey Medical School, Newark, NJ 07103, USA.
Carla RomagnoliMount Sinai Medical Center, Miami Beach, FL 33140, USA.ORCID 0009-0005-8176-2342
Jose SandovalMoffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System, Pembroke Pines, FL 33028, USA.
Yelida BrauchleMount Sinai Medical Center, Miami Beach, FL 33140, USA.
Alexandra LyubimovaMount Sinai Medical Center, Miami Beach, FL 33140, USA.
Leily SantosMount Sinai Medical Center, Miami Beach, FL 33140, USA.
Evelyn Goya BalaguerMount Sinai Medical Center, Miami Beach, FL 33140, USA.
Jacqueline BarrientosMount Sinai Medical Center, Miami Beach, FL 33140, USA.ORCID 0000-0001-6018-5535

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapy for chronic lymphocytic leukemia (CLL) has evolved dramatically with the introduction of targeted agents, particularly Bruton tyrosine kinase inhibitors (BTKis) and BCL2 inhibitors (BCL2is). This review summarizes contemporary frontline and relapsed/refractory treatment strategies, with an emphasis on molecular risk stratification, combination and triplet regimens, measurable residual disease (MRD)-guided therapy, and time-limited approaches. We further examine how genomic complexity, prior therapies, and sociodemographic factors influence disease progression, treatment resistance, and clinical outcomes.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellAgammaglobulinaemia Tyrosine KinaseHumansMolecular Targeted TherapyProtein Kinase InhibitorsProto-Oncogene Proteins c-bcl-2Agammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsProto-Oncogene Proteins c-bcl-2BCL-2 inhibitorsBTK inhibitorschronic lymphocytic leukemiacomplex karyotypeIGHVprognostic scoresTP53 abnormalities

Identifiers

PMID42278639
PMCPMC13256845

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.